Greenwich LifeSciencesGLSI -6.78%33 Quick Ratio is 2.01 as of Mar. 2026, which is 89% below its 10-year median of 18.95. GuruFocus rates GLSI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,417 Biotechnology companies, Greenwich LifeSciences ranks worse than 65.35% on this metric.
Greenwich LifeSciences has a quick ratio of 2.01. It generally indicates good short-term financial strength.
The historical rank and industry rank for Greenwich LifeSciences's Quick Ratio or its related term are showing as below:
GLSI'
s Quick Ratio Range Over the Past 10 Years
Min: 0.01 Med: 18.95 Max: 81.92
Current: 2.01
During the past 8 years, Greenwich LifeSciences's highest Quick Ratio was 81.92. The lowest was 0.01. And the median was 18.95.
GLSI's Quick Ratio is ranked worse than 65.35% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs GLSI: 2.01
Greenwich LifeSciences (NAS:GLSI) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Greenwich LifeSciences Quick Ratio Related Terms
Greenwich LifeSciences Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Greenwich LifeSciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Greenwich LifeSciences Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Greenwich LifeSciences's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Greenwich LifeSciences's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Greenwich LifeSciences's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Greenwich LifeSciences (GLSI) has a Quick Ratio of 2.01 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Greenwich LifeSciences and its competitors. This is 89% below median its historical median of 18.95. Over the past decade, Greenwich LifeSciences' Quick Ratio has ranged from 0.01 to 81.92. According to the industry distribution chart, Greenwich LifeSciences ranks #926 out of 1417 companies in the Biotechnology industry, placing it in the top 65.3%.
Is Greenwich LifeSciences' Quick Ratio too high?
Greenwich LifeSciences' current Quick Ratio of 2.01 is 89% below median its 10-year median of 18.95. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 81.92. The Biotechnology industry median Quick Ratio is 3.60. Greenwich LifeSciences' value of 2.01 is 44.2% below this industry median. Based on the distribution chart, Greenwich LifeSciences ranks #926 out of 1417 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Greenwich LifeSciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Greenwich LifeSciences' Quick Ratio compare to LRMR and RGNX?
According to the Biotechnology industry distribution chart, Greenwich LifeSciences ranks #926 out of 1417 companies for Quick Ratio. This places Greenwich LifeSciences in the lower half of its industry. The industry median Quick Ratio is 3.60. Greenwich LifeSciences' value of 2.01 is 44.2% below this benchmark. Historically, Greenwich LifeSciences' own Quick Ratio has ranged from 0.01 to 81.92 over the past decade. While the company's 10-year median is 18.95 vs. the industry median of 3.60, Greenwich LifeSciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Greenwich LifeSciences's current Quick Ratio of 2.01 is 44.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Greenwich LifeSciences and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Greenwich LifeSciences's current Quick Ratio is 2.01, which is 89% below median its own 10-year median of 18.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greenwich LifeSciences stock overvalued right now?
Greenwich LifeSciences (GLSI) has a current Quick Ratio of 2.01. The current Quick Ratio is 2.01, which is 89% below median its 10-year median of 18.95 and 44.2% below the Biotechnology industry median of 3.60. Greenwich LifeSciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Greenwich LifeSciences (GLSI), the current Quick Ratio is 2.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
33GF Score
Get the complete analysis for GLSI
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLSI has been successfully added to your 
